Effect of alemtuzumab on neoplastic B cells

Haematologica

Volumn 89, Issue 12, 2004, Pages

  Golay, Josée ^a   Manganini, Massimiliano ^a   Rambaldi, Alessandro ^a   Introna, Martino ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Alemtuzumab; B cell neoplasia; Complementcytotoxicity

Indexed keywords

ALEMTUZUMAB; RITUXIMAB;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOLYSIS; DRUG EFFICACY; DRUG MECHANISM; EFFECTOR CELL; EVALUATION; FEMALE; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; MALE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROLYMPHOCYTIC LEUKEMIA; REGULATORY MECHANISM;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL LINE, TUMOR; COMPLEMENT ACTIVATION; CYTOTOXICITY, IMMUNOLOGIC; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLYCOPROTEINS; HUMANS; INTERLEUKIN-2; LEUKEMIA, B-CELL, CHRONIC; LEUKEMIA, HAIRY CELL; LEUKEMIA, PROLYMPHOCYTIC; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED;

EID: 19744361832     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-7.
2. Hale G, Xia MQ, Tighe MJS, Waldmann H. The Campath-1H antigen (CDw52). Tissue antigens 1990;35:118-27.
3. Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002;99:2586-91.
4. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003;101:1422-9.
5. Dyer MJD. The role of Campath-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999;26:52-7.
6. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1 H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61.
7. Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278-81.
8. Oesterborg A, Dyer MJS, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 1997;15:1567-74.
9. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891-7.
10. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-73.
11. Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, Horowitz MM, et al. Improving outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998;92:4581-90.
12. Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitsky N, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000;26:69-76.
13. Hale G, Slavin S, Goldman JM, Mackinnon S, Giralt S, Waldmann H. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of non-myeloablative conditioning? Bone Marrow Transplant 2002;30:797-804.
14. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following non-myeloablative stem cell transplantation. Blood 2000;96:2419-25.
15. Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002;100:3121-7.
16. Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002;100:1715-20.
17. D'Sa S, Peggs K, Pizzey A, Verfuerth S, Thuraisundaram D, Watts M, et al. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. Br J Haematol 2003;123:309-22.
18. Waldmann H. Therapeutic approaches for transplantation. Curr Opin Immunol 2001;13:606-10.
19. Rebello P, Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods 2002;260:285-302.
20. Khouri IF, Albitar M, Saliba RM, Ippoliti C, Ma YC, Keating MJ, et al. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant 2004;33:833-7.
21. Wing MG, Moreau T, Greenwood J, Smith RM, Hale G, Isaacs J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996;98:2819-26.
22. Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res 2003;63:6453-7.
23. Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 1993;23:1098-104.
24. Xia MQ, Hale G, Lifely MR, Ferguson MA, Campbell D, Packman L, et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993;293:633-40.
25. Moreton P, Hillmen P. Alemtuzumab therapy in B-cell lymphoproliferative disorders. Semin Oncol 2003;30:493-501.
26. Zent CS, Chen JB, Kurten RC, Kaushal GP, Marie Lacy H, Schichman SA. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 2004;28:495-507.
27. Dyer MJ, Hale G, Hayhoe FG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989;73:1431-9.
28. Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol 2003;30:483-92.
29. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14:520-35.
30. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri G, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-8.
31. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al. CD20 levels determine the in vitro susceptbility to rituximab and complement of B-cell chronic lymohocytic leukaemia: further regulation by CD55 and CD59. Blood 2001;98:3383-9.
32. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29 Suppl 2:2-9.
33. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003;30:3-8.
34. Golay J, Gramigna R, Facchinetti V, Capello D, Gaidano G, Introna M. Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituxlmab. Br J Haematol 2002;119:923-9.
35. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185-91.
36. Bass AJ, Gong J, Nelson R, Rizzieri DA. CD52 expression in mantle cell lymphoma. Leuk Lymphoma 2002;43:339-42.
37. Quigley MM, Bethel KJ, Sharpe RW, Saven A. CD52 expression in hairy cell leukemia. Am J Hematol 2003;74:227-30.
38. Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G, et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003;88:1002-12.
39. Belosillo B, Villamor N, Lopez-Guillermo A, Marcé S, Esteve J, Campo E, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001;98:2771-7.
40. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-7.
41. Cragg MS, Glennie M. Antibody specific controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2003;103:1238-43.
42. Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Osterborg A. Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001;2:300-6.
43. Dunne J, Lynch S, O'Farrelly C, Todryk S, Hegarty JE, Feighery C, et al. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 2001;167:3129-38.
44. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural killer cell surveillance and therapy of cancer. Nat Rev Cancer 2002;2:850-61.
45. Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, Malaspina A, et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999;189:787-96.
46. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. Embo J 2004;23:255-9.
47. Campbell KS, Yusa S, Kikuchi-Maki A, Catina TL NKp44 triggers NK cell activation through DAP12 association that is not influenced by a putative cytoplasmic inhibitory sequence. J Immunol 2004;172:899-906.
48. Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother 1998;46:318-26.
49. rd, Caligiuri M, et al. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res 2002;8:3718-27.
50. Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004;10:2253-64.